Merck (MRK) Tops Q3 EPS by 18c

Merck (NYSE: MRK) reported Q3 EPS of $2.13, $0.18 better than the analyst estimate of $1.95. Revenue for the quarter came in at $16 billion versus the consensus estimate of $15.29 billion.

GUIDANCE:

Merck sees FY2023 EPS of $3.03-$3.08, ex items, versus the consensus of $2.86. Merck sees FY2023 revenue of $59.7-60.2 billion, versus the consensus of $55.98 billion.

For earnings history and earnings-related data on Merck (MRK) click here.

You May Also Be Interested In

• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
• Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan
• UBS Reiterates Neutral Rating on Pilgrim's Pride (PPC) on 'Challenging' Near-Term Fundamentals